Kintara Therapeutics (NASDAQ:KTRA) Stock Price Down 4.7%

Shares of Kintara Therapeutics, Inc. (NASDAQ:KTRA) fell 4.7% during mid-day trading on Wednesday . The stock traded as low as $0.15 and last traded at $0.15. 1,881,400 shares changed hands during trading, a decline of 86% from the average session volume of 13,411,562 shares. The stock had previously closed at $0.16.

Kintara Therapeutics Price Performance

The company has a 50 day simple moving average of $0.11 and a 200-day simple moving average of $0.48. The stock has a market cap of $5.78 million, a P/E ratio of -0.02 and a beta of 0.57.

Kintara Therapeutics (NASDAQ:KTRA) last issued its quarterly earnings results on Wednesday, February 14th. The company reported ($0.24) earnings per share (EPS) for the quarter.

Kintara Therapeutics Company Profile

Kintara Therapeutics, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients.